Jump to main content
Jump to site search

Issue 8, 2016
Previous Article Next Article

Point of care testing of phospholipase A2 group IIA for serological diagnosis of rheumatoid arthritis

Author affiliations

Abstract

Secretory phospholipase A2 group IIA (sPLA2-IIA) was examined as a point of care marker for determining disease activity in rheumatoid (RA) and psoriatic (PsA) arthritis. Serum concentration and activity of sPLA2-IIA were measured using in-house antibodies and a novel point of care lateral flow device assay in patients diagnosed with varying severities of RA (n = 30) and PsA (n = 25) and found to correlate strongly with C-reactive protein (CRP). Levels of all markers were elevated in patients with active RA over those with inactive RA as well as both active and inactive PsA, indicating that sPLA2-IIA can be used as an analogue to CRP for RA diagnosis at point of care.

Graphical abstract: Point of care testing of phospholipase A2 group IIA for serological diagnosis of rheumatoid arthritis

Back to tab navigation

Supplementary files

Publication details

The article was received on 27 Nov 2015, accepted on 25 Jan 2016 and first published on 01 Feb 2016


Article type: Communication
DOI: 10.1039/C5NR08423G
Citation: Nanoscale, 2016,8, 4482-4485
  •   Request permissions

    Point of care testing of phospholipase A2 group IIA for serological diagnosis of rheumatoid arthritis

    N. J. Liu, R. Chapman, Y. Lin, J. Mmesi, A. Bentham, M. Tyreman, S. Abraham and M. M. Stevens, Nanoscale, 2016, 8, 4482
    DOI: 10.1039/C5NR08423G

Search articles by author

Spotlight

Advertisements